Donor-specific Cell-free DNA as a Biomarker in Solid Organ Transplantation. A Systematic Review
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background: There is increasing interest in the use of noninvasive biomarkers to reduce the risks posed by invasive biopsy for monitoring of solid organ transplants (SOTs). One such promising marker is the presence of donor-derived cell-free DNA (dd-cfDNA) in the urine or blood of transplant recipients. Methods: We systematically reviewed the published literature investigating the use of cfDNA in monitoring of graft health after SOT. Electronic databases were searched for studies relating cfDNA fraction or levels to clinical outcomes, and data including measures of diagnostic test accuracy were extracted. Narrative analysis was performed. Results: Ninety-five articles from 47 studies met the inclusion criteria (18 kidneys, 7 livers, 11 hearts, 1 kidney-pancreas, 5 lungs, and 5 multiorgans). The majority were retrospective and prospective cohort studies, with 19 reporting diagnostic test accuracy data. Multiple techniques for measuring dd-cfDNA were reported, including many not requiring a donor sample. dd-cfDNA falls rapidly within 2 weeks, with baseline levels varying by organ type. Levels are elevated in the presence of allograft injury, including acute rejection and infection, and return to baseline after successful treatment. Elevation of cfDNA levels is seen in advance of clinically apparent organ injury. Discriminatory power was greatest for higher grades of T cell–mediated and antibody-mediated acute rejection, with high negative predictive values. Conclusions: Cell-free DNA is a promising biomarker for monitoring the health of SOTs. Future studies will need to define how it can be used in routine clinical practice and determine clinical benefit with routine prospective monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Identification of tissue-specific cell death using methylation patterns of circulating DNA
Lehmann-Werman, R., Neiman, D., Zemmour, H., Moss, J., Magenheim, J., Vaknin-Dembinsky, A., Rubertsson, S., Nellgård, B., Blennow, K., Zetterberg, H., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519286113 · Cited by 610 · cited 1×
“Methods have been described to determine the origin of circulating cfDNA using organ-specific methylation patterns.(109) Use of beta cell-specific cfDNA detection has already been reported in the context of clinical islet cell transplantation.”
MethodCell-Free DNA and Active Rejection in Kidney Allografts
Bloom, R. D., Bromberg, J. S., Poggio, E. D., Bunnapradist, S., Langone, A. J., Sood, P., Matas, A. J., Mehta, S., Mannon, R. B., Sharfuddin, A., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016091034 · Cited by 584 · cited 7×
“All but one study reporting on kidney transplant recipients demonstrated significant elevations in ddcfDNA levels at the time of BPAR.”
BackgroundMethodResultInfluentialCirculating Cell-Free DNA Enables Noninvasive Diagnosis of Heart Transplant Rejection
De Vlaminck, I., Valantine, H. A., Snyder, T. M., Strehl, C., Cohen, G., Luikart, H., Neff, N. F., Okamoto, J., Bernstein, D., Weisshaar, D., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007803 · Cited by 549
Universal noninvasive detection of solid organ transplant rejection
Snyder, T. M., Khush, K. K., Valantine, H. A., & Quake, S. R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013924108 · Cited by 385 · cited 1×
“Themost straightforward method used in the included studies is the detection of the sex-determining region Y or testes-specific protein Y-linked Y-chromosome repeat in female recipients of male organs.(31,32,39,53,81,102) Although simple to detect and not requiring donor material for genotyping, this limits dd-cfDNA q…”
MethodNoninvasive monitoring of infection and rejection after lung transplantation
De Vlaminck, I., Martin, L., Kertesz, M., Patel, K., Kowarsky, M., Strehl, C., Cohen, G., Luikart, H., Neff, N. F., Okamoto, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517494112 · Cited by 349
Beck, J., Bierau, S., Balzer, S., Andag, R., Kanzow, P., Schmitz, J., Gaedcke, J., Moerer, O., Slotta, J. E., Walson, P., et al. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.210328 · Cited by 271 · cited 3×
“In liver recipients, levels elevate with active hepatitis B and C infection,(44,53,55) but not with cholestasis.(44,48,99) In lung recipients, elevated levels are seen in recipientswith infections associated with chronic lung allograft dysfunction.”
BackgroundResultGrskovic, M., Hiller, D. J., Eubank, L. A., Sninsky, J. J., Christopherson, C., Collins, J. P., Thompson, K., Song, M., Wang, Y. S., Ross, D., et al. (2016) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.07.003 · Cited by 258 · cited 1×
“Although earlier studies required initial detection of SNPs in both donor and recipient samples to detect informative mismatches, more recent studies have used computational approaches to determine the minor donor type, removing the requirement for donor samples and typing.(15,30,55,61,99,101)”
ResultSchütz, E., Fischer, A., Beck, J., Harden, M., Koch, M., Wuensch, T., Stockmann, M., Nashan, B., Kollmar, O., Matthaei, J., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002286 · Cited by 223
Cited by
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Brunet, M., van Gelder, T., Åsberg, A., Haufroid, V., Hesselink, D. A., Langman, L., Lemaitre, F., Marquet, P., Seger, C., Shipkova, M., et al. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000640 · Cited by 707
Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
Keller, L., Belloum, Y., Wikman, H., & Pantel, K. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01047-5 · Cited by 401
Sigdel, T., Archila, F., Constantin, T., Prins, S., Liberto, J., Damm, I., Towfighi, P., Navarro, S., Kirkizlar, E., Demko, Z., et al. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm8010019 · Cited by 219
Harmonizing Cell-Free DNA Collection and Processing Practices through Evidence-Based Guidance
Greytak, S. R., Engel, K. B., Parpart-Li, S., Murtaza, M., Bronkhorst, A. J., Pertile, M. D., & Moore, H. M. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3015 · Cited by 140
Metadata
- Authors
- Knight, S. R., Thorne, A., & Lo Faro, M. L.
- Venue
- Transplantation
- Published
- 2019-02
- Volume
- 103
- Issue
- 2
- Pages
- 273-283
- ISSN
- 0041-1337 (ISSN-L)
- 1534-6080
- OpenAlex
- W2897984237
- Cited by
- 204
- References
- 31
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Donor-specific Cell-free DNA as a Biomarker in Solid Organ Transplantation. A Systematic Review. https://app.cochat.ai/papers/10.1097/tp.0000000000002482
- The paper
- Knight, S. R., Thorne, A., & Lo Faro, M. L. (2019). Donor-specific Cell-free DNA as a Biomarker in Solid Organ Transplantation. A Systematic Review. Transplantation. https://doi.org/10.1097/tp.0000000000002482
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.